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a  b  s  t  r  a  c  t
INTRODUCTION:  With  increasing  incidence  of  breast  cancers  there  are  now  a larger  number  of  cases
diagnosed  with  rare  malignancies.  These  can  be  diagnostic  dilemmas  and  management  strategy  can  be
different  by  various  breast  multi-disciplinary  teams  (MDT).
We  aim  to  discuss  the  evidence-based  approach  for management  of  these  atypical  breast  cancers  which
were  identiﬁed  in patients  from  a single  breast  screening  unit.
METHOD:  Patient  with  unusual  breast  malignancies  (all types  except  invasive  ductal  and  lobular)  treated
under  the  care  of  a single  surgeon  were  identiﬁed  during  the  breast  multi-disciplinary  discussion  from
2011  to 2015.  The  histology  and  management  of these  cases  were  reviewed  and  literature  search  ofucinous carcinoma
pocrine carcinoma
electronic  databases  via  PubMed  and the  search  engines  Google/Google  Scholar  was performed.  Emphasis
on keywords  based  on the  histology  type was  used  to limit  search.  Search  was  focused  on the  diagnosis,
management  and  prognosis  of these  unusual  breast  cancers.
CONCLUSION:  This  series  aims  to  focus  on  the  evidence-based  management  of  these  rare  breast  malig-
nancies;  the  diagnosis  of which  is crucial  as it affects  the  overall  treatment  and  prognosis.
©  2016  The  Authors.  Published  by Elsevier  Ltd.  on  behalf  of  IJS Publishing  Group  Ltd.  This is  an  open
he  CCaccess  article  under  t
. Introduction
Breast cancer is a heterogeneous condition of which there is a
igh degree of variation between and within tumours [1]. Despite
he small number of cases that consist of atypical breast malignan-
ies, the rising rate of breast cancers has created a larger proportion
f rare malignancies.
This is a series of some atypical breast cancers encountered
uring one surgeon’s practice. Including a case of malignant
yoepithelioma which is an extremely rare entity and diagnostic
hallenge for the breast multi-disciplinary team (MDT). Along with
his we report interesting cases of invasive mucinous carcinoma
nd apocrine carcinoma which are less widely seen than the more
ommonly seen invasive ductal and lobular cancers but require vig-
lance of their variable characteristics to ensure right management
2].
The aim of these cases is to discuss the evidence based approach
or these cancers following our previous review [3].∗ Corresponding author.
E-mail addresses: luciejwright@doctors.org.uk (L. Wright), isao.nce@gmail.com
C.E. Ng), tani.fasih@ghnt.nhs.uk (T. Fasih).
ttp://dx.doi.org/10.1016/j.ijscr.2016.01.008
210-2612/© 2016 The Authors. Published by Elsevier Ltd. on behalf of IJS Publishing G
reativecommons.org/licenses/by-nc-nd/4.0/). BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2. Malignant myoepithelioma of breast
2.1. Case report
A 58 year old lady who  was  known to have a ductal adenoma of
her left breast for 3 years was  identiﬁed on screening mammogram
which suggested that the adenoma had enlarged in size and looked
atypical in appearance and was graded as indeterminate on mam-
mogram (M3). She underwent an ultrasound of the breast which
suggested this to be a suspicious lesion (U4). A ﬁne needle aspi-
ration (FNA) biopsy was  performed for the lesion this suggested
a cellular aspirate with benign ductal epithelial cells, some show-
ing apocrine changes associated with myoepithelial cells. As such,
cytology was  overall graded as indeterminate in nature (C3). The
patient underwent a core biopsy of the lump and this revealed an
atypical ductal lesion with cellular and nuclear atypica, moreover
myoepithelial cells were seen throughout most of the lesion. The
differentiation between an adenoma and adenoma–myoepithelial
lesion could not be made and therefore a diagnostic biopsy of the
lesion was performed which suggested a grade 3 metaplastic carci-
noma in an existing adenomyoepithelioma. The tumour measured
19 mm  with clear excision margins. Due to the complexity around
histological analysis, the case was referred to experts in a tertiary
centre for their views. A detailed report reads as follows: ‘a tumour
from an admixture of relatively scanty tubular structures with sur-
rounding cells of variable appearance. For the most part these latter
are also rather epithelioid with abundant cytoplasm and large nuclei
and elsewhere more spindle in nature (Fig. 1). Immunohistochemistry
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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iig. 1. Malignant adenomyoepithelioma with a central component of small well-
ormed tubules and spindle cells, and a more atypical epithelioid component at the
eriphery.
or smooth muscle myosin (SMM)  appears to show myoepithelial cells.
any of the immunohistochemistry suggested dual population of cells,
he tubular structure was positive with epithelial membrane antigen
EMA) and focally with oestrogen receptor (ER), although not pro-
esterone receptors and HER 2 is negative too. The tubular portions
tain up particularly strongly with CK7, although the surrounding cells
lso show reactivity. The latter are conﬁrmed to be of myoepithelial
henotype with smooth muscle actin (SMA), smooth muscle myosin
eavy chain (SMMHC) and p63. Staining for CK5/6 and S100 was seen
hroughout the lesion but more pronounced in the atypical periphery.
ven within the peripheral, well-deﬁned islands of more atypical forms,
here is still immunopositivity with both epithelial and myoepithelial
arkers in adjacent cells within an individual cluster indicating there
s an underlying dual phenotype. Therefore it is advised to best regard
t as malignant adenomyoepithelioma based on the morphology and
mmunopattern.’
After conﬁrming the diagnosis of malignant myoepithelioma,
he patient subsequently underwent radiotherapy to the affected
reast for 3 weeks with 15 Gy given in 15 fractions over 21 day
eriod. Due to ER positivity adjuvant endocrine treatment in the
orm of Letrozole 2.5 mg  once a day was commenced. She has
emained well and has been disease free for 22 months.
.2. Literature review
Myoepithelial cells are located around sweat, lacrimal, and sali-
ary glands, and also seen around the secretory alveoli of mammary
lands [4]. Myoepithelium has both epithelial and smooth muscle
ells and tumours arising from this site are called myoepitheliomas.
lthough breast glands like the salivary glands are tubulo-acinar
xocrine glands, myoepitheliomas are very rare in breast tissue
ompared to the salivary glands [5].
Tavassolvi described 3 types of these lesions—myoepithelioma,
denoepithelioma and the sinister variant malignant myoep-
thelioma [6]. Besides the breast other rare sites of malignant
yoepitheliomas are reported on the skin, lungs [7], vulva [4] and
asopharynx.
The World Health Organization (WHO) recognised this entity in
919 and according to this classiﬁcation; myoepithelial carcinoma
s composed almost exclusively of tumour cells with myoepithelial
ifferentiation [6,8].
The mean age of presentation is the 5th decade [5,8] with
omen presenting with a painless breast lump. Diagnosis is made
n immunohistochemistry using antibodies to broad-spectrum
eratins, p63 and antibodies to myoﬁlament. Antibodies namely
10, p63, S100 protein, -smooth muscle actin (SMA), caldesmon
re considered the common markers for detecting these lesions.
ur case was labelled as malignant myoepithelioma after the
mmunohistochemistry showed positivity to p63, S100 and SMA;
n short it was found to have immunnopositivity for bothFig. 2. Invasive mucinous carcinoma composed of sheets of monotonous atypical
epithelial cells within dissecting pools of mucin.
epithelial and myoepithelial markers, which is typical of myoep-
ithelial carcinoma cells.
Malignant myoepitheliomas tend to be negative for oestrogen
receptors [ER] [9] and for this reason Suguna et al. [8] suggested that
all ER negative breast cancers should have myoepithelial markers
tested as a signiﬁcant number (29%) of these exhibit these markers
[9]. Although the vast majority are ER negative cancer, in our case
due to the dual population identiﬁed in the lesion with a small
tubular structure in the centre which was ER positive, she was
commenced on an aromatase inhibitor.
Treatment for myoepitheliomas is surgical excision of the lesion
followed by radiotherapy to the breast for breast conserving pro-
cedures to prevent local recurrence [4]. In a report by Tsuda [10] 6
patients were treated by local excision and only 1 patient received
radiotherapy treatment, as a consequence 3 of the patients devel-
oped local recurrence. The dose of radiotherapy is variable and
some have recommend 50 Gy radiotherapy in 15–25 fractions. In
our case, the patient received 3 weeks of radiotherapy at 15 Gy in
15 fractions and has remained disease free to date.
These cancers have a tendency to metastasize to viscera’s like
lungs and brain [5,10] and are found to be aggressive in nature [7]
despite this, the role of chemotherapy is controversial and there is
no consensus of its use [8]. In a study by Behranwala et al. [11], the
2-year and 5-year survival was 88% and 55% respectively.
3. Mucinous carcinoma of the breast
3.1. Case report 1
A 69 year old lady who was  identiﬁed through breast screening
in December 2012 for a new stellate mass found in her left breast
which appeared highly suspicious of cancer (M4). She underwent
both FNA and core biopsy of this lesion. FNA suggested a moderate
yield of malignant cells in crowded clusters with a large amount
of mucin in the background. These appearances were in keeping
with a special mucinous type breast carcinoma. The core biopsy
of the lesion conﬁrmed an invasive mucinous carcinoma which
was oestrogens receptor (ER) positive and HER2 negative. A staging
scan revealed no abnormal appearance of axillary nodes. She subse-
quently underwent a wide local excision and sentinel node biopsy.
Histology following this, showed a grade 2 invasive mucinous carci-
noma comprising of mucin lakes in which small nests of malignant
epithelial cells were suspended within the breast tissue as seen in
Fig. 2. There were also associated micro calciﬁcation as well as high
grade DCIS with a cribriform architecture; associated with this was
lymphovascular space invasion in the tissue. In summary, she had
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 grade 2 invasive mucinous carcinoma which measured 9.6 mm
ith a whole tumour size including DCIS of 11 mm.  The 2 sentinel
odes that were removed were found to be free of metastasis.
She was subsequently referred for radiotherapy treatment with
he oncologist and was also started on Letrozole 2.5 mg  to be taken
nce a day. She received 40 Gy in 15 fractions to the left breast over
 period of 3 weeks.
The patient remains well and after 3 years of follow up there is
o evidence of local recurrence or distant metastasis.
.2. Case report 2
A 48 year old lady presented to the symptomatic clinic with 6–7
onth history of left breast pain. On examination she had teth-
ring of the skin on the left breast most noticeable when raising
er arm. A 5 cm ﬁrm lump underneath the left sub areola area was
dentiﬁed and she underwent mammography which identiﬁed a
6 mm ill-deﬁned opacity of unclear nature (M3). On ultrasound
he lesion looked more like a haematoma (U2). Following this she
ad a FNA and a core biopsy; FNA cytology revealed dispersed
onomorphic small to medium sized atypical cells with hyper-
hromatic nuclei and moderate cytoplasm containing intra nuclear
acuoles, with mucin present in the background. The appearances
ere suggestive of a mucinous carcinoma (C5). The core biopsy of
he lump conﬁrmed features of invasive mucinous carcinoma grade
 (B5b). Due to the size of the lump she underwent mastectomy
nd axillary node sampling. Microscopy of the specimen revealed a
ell circumscribed and partially encapsulated tumour composed of
umour cell nests ﬂoating within lakes of mucin measuring 35 mm.
he appearances were most in keeping with a grade 1 invasive
ucinous carcinoma. There was possible lymphovascular space
nvasion seen and tumour was found to be oestrogen positive (ER)
nd HER 2 negative. 1 out of 3 sentinel nodes removed showed
etastatic carcinoma and therefore she underwent axillary clear-
nce but no further malignancy was found in the nodes. After
iscussing her case in the breast MDT  she was  recommended to
ndergo chemotherapy treatment followed by 5 years of endocrine
reatment. She had chemotherapy in the form of 6 courses of
 Fluorouracil (FU), Epirubicin and Cyclophosphamide. She ini-
ially accepted to take part in the SUPREMO trial (Selective Use of
ostoperative Radiotherapy aftEr MastectOmy) which randomises
atients with 1–3 positive nodes to either chest wall radiotherapy
ersus no further treatment. She has since refused to undergo any
urther treatment and currently remains well four years after her
riginal operation and has also underwent breast reconstruction.
.3. Case report 3
A 63 year old lady was identiﬁed from breast screening in
ovember 2011 with a poorly deﬁned opacity in the right upper
nner breast. On mammogram there was a 13 mm stellate lesion
nd had features consistent of a carcinoma (M5) but an ultrasound
f the breast was not able to identify this area. A FNA of the lesion
as performed which revealed paucicellular specimen containing
 few benign ductal epithelial cells only. However, on the core
iopsy performed a special type mucinous carcinoma was  identi-
ed which was  oestrogen receptor positive (ER) and HER2 negative.
he underwent a wide local excision and sentinel node biopsy and
istology of the tissue removed showed a 20 mm grade 1 inva-
ive mucinous adenocarcinoma with presence of lymphovascular
nvasion. 1 of the sentinel lymph node showed positive staining
ith S100, HMB45 and melan-A indicating there were melanocytes
resent. This patient previously had a nodular malignant melanoma
xcised early that year and the features suggested metastatic malig-
ant melanoma. Fortunately, there was no evidence of mucinous
denocarcinoma metastasis to the axilla. Her case was discussed inPEN  ACCESS
rgery Case Reports 20 (2016) 41–45 43
MDT  and she was  referred to the melanoma team for axillary block
dissection. She also received postoperative radiotherapy 40 Gy in
15 fractions over 22 days to the right breast. After 4 years of follow
up since her original surgery she remains symptom free.
3.4. Literature review
Mucinous carcinoma of the breast is estimated to account for
less than 5.5% of all breast cancers [12]. The incidence for this type
of cancer in literature is variable due to histological variability with
some carcinomas being purely mucinous and others being mixed
in nature.
Mucinous carcinoma is deﬁned as tumour containing a muci-
nous component of 50% or more [9,13]. Although some describe the
amount of mucin could be lower than that (>33–50%) and still be
considered as mucinous carcinoma [9]. On histology these cancers
have clusters of neoplastic cells suspended in extra cellular mucin
[14]. There are 2 broad classiﬁcations based on the amount of mucin
present; one is a pure mucinous breast carcinoma (PMBC) and the
other type is a mixed mucinous breast carcinoma (MMBC). WHO
has deﬁned PMBC as consisting exclusively of tumour tissue with
extracellular mucin production while MMBC  is a tumour where
there are area of both mucinous and inﬁltrating ductal epithelial
component [12]. Pure mucinous cancers are seen in 2–3% of all
invasive cancers and majority; like all our cases reported belong
to the mixed mucinous group.
This is a helpful distinction as it has been suggested that pure and
mixed carcinomas differ signiﬁcantly with respect to prognostic
factors. Rasmussen et al. [15] found that patients with pure muci-
nous carcinomas had fewer lymph node metastases at the time of
primary operation and a longer recurrence-free survival times than
those with mixed carcinomas. The same conclusion was  reported
by Komaki et al. who  showed the 10-year survival rate of PMBC
being 90.4% compared to 66.0% in MMBC.
Age of presentation is variable but generally it affects older pop-
ulation with a median age of 55–60 years [9,16].
The presentation of mucinous carcinoma is highly variable and
there is debate about common characteristics on mammography.
One study examining PMBC found that although majority of the
lesions (87%) were palpable clinically but 1/3rd (17%) of these were
not visible on mammogram [15]. They can have well deﬁned mar-
gins on the X-rays unlike the classical ill-deﬁned margins of a cancer
and could mislead for benign lesions.
Surgical treatment involves local excision of the lump or
mastectomy with sentinel node mapping. This is followed by
chemotherapy, adjuvant radiotherapy in case of breast conserv-
ing surgery and endocrine treatment. The drug of choice for
chemotherapy is anthracycline based.
The prognosis for patients with mucinous breast cancer is gen-
erally favourable with a 10 year survival of more than 90% for pure
mucinous cancer [17]. When compared to ductal carcinomas, muci-
nous carcinomas tend to be of a lower grade at time of detection [18]
and have a low incidence of lymph node metastasis and recurrence
rate. A wide ranging study using the Netherlands Cancer Registry
showed that there was a better age, stage and grade adjusted prog-
nosis for patients with mucinous carcinoma when compared to
invasive ductal carcinomas [19].
Positive nodal status has been reported as being the most sig-
niﬁcant predictor of worse prognosis [20]. As far as the tumour size
is concerned, there is debate on whether the tumour size has an
impact on survival or not. There are studies correlating larger size
with a poorer prognosis compared to others where no signiﬁcant
impact on survival based on tumour size has been found [21]. This
is potentially because the volume of mucin surrounding the tumour
can mean the true size of the tumour can be difﬁcult to deter-
mine. Although size of the tumour is not an important factor to
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Cig. 3. Invasive apocrine carcinoma composed of cells with abundant eosinophilic
nd  ﬁnely granular cytoplasm.
etermine the prognosis as the bulk of the tumour is given by
he mucin which is considered to overestimate the tumour size.
owever the presence of mucin is found to give resistance to
ranstuzumab and these cancers are found to be HER 2 negative
13]. Although nodal status is a sign of poor prognosis but nodal
nvolvement is rare in such cancers with nodal disease from 12
o 19% reported [9]. For this reason there have been suggestion to
void nodal dissection when removing the mucinous cancer [21].
. Invasive apocrine breast cancers
.1. Case report 1
This 60 year old lady was  seen at the screening clinic in February
011 after being diagnosed with right breast cancer on screening
ammogram. The tumour measured 5 mm on mammogram (M3)
ut was not visible on ultrasound. FNA was not performed but she
nderwent a vacuum-assisted core biopsy (VACB) of this area. This
howed pieces of generally markedly hyalinised breast tissue with
vidence of active chronic inﬂammation, associated with atypical
pocrine appearing areas. These were markedly atypical, with areas
f calciﬁcation seen within it. The appearances suggested an apoc-
ine high grade DCIS. In addition, there were areas of atypical cells
resent as cords and columns within the stroma and the sample was
nterpreted as an invasive ductal carcinoma grade 2, with apocrine
eatures. After discussing her case in the breast MDT  she was rec-
mmended to undergo breast conserving surgery and sentinel node
iopsy. Histology of the breast tumour removed showed a small
ocus of residual high grade DCIS with micro papillary and comedo
rowth patterns. There was a 5 mm focus of invasive carcinoma
omposed of solid islands of tumour cells which have abundant
osinophilic cytoplasm and round nuclei with prominent central
uclei as seen in Fig. 3. The appearances were those of a grade 2
nvasive apocrine carcinoma which was oestrogen receptor nega-
ive (ER) but HER2 positive. 2 sentinel nodes were removed and
hese were found to be free of metastasis. She only underwent
ostoperative radiotherapy of 40 Gy in 15 fractions over 22 days to
he right breast even though it was recommended for her to have
hemotherapy and Herceptin treatment. She has remained disease
ree four years since her treatment.
.2. Case report 2This 67 year old lady was referred to the symptomatic clinic
ith a chance ﬁnding of a lesion identiﬁed in her left breast on her
T chest organised for investigation of upper GI symptoms. ThisPEN  ACCESS
rgery Case Reports 20 (2016) 41–45
showed an ill-deﬁned enhancing nodular area in the outer aspect
of the left breast measuring 16 mm.  Clinically there was no palpable
lump but on mammography an 18 mm irregular density in the left
upper outer breast was identiﬁed which looked suspicious for can-
cer (M4). An ultrasound scan of the left breast was also performed
and revealed this lesion to be a 16 mm irregular solid mass con-
sistent with malignancy (U5). A FNA and core biopsy of the lesion
was performed. The FNA examination revealed a cellular specimen
with the best preserved cells seen with numerous sheets of apoc-
rine cells and variable nuclear pleomorphism. There appeared to
be myoepithelial cells in the background raising the possibility of
an apocrine variant of ductal carcinoma. A core biopsy of this area
showed invasive ductal carcinoma grade 2 with apocrine architec-
ture and the tumour was  found to be ER and Her2 negative. This
lady opted for wide local excision and sentinel node biopsy. Her
ﬁnal histology conﬁrmed a 12 mm  grade 2 invasive apocrine car-
cinoma and the sentinel nodes removed were free of metastasis.
MDT recommended radiotherapy and chemotherapy treatment for
this lady. She completed 6 cycles of FEC (Fluorouracil, Cyclophos-
phamide and Epirubicin) followed by radiotherapy to the breast in
the form of 40 Gy in 15 fractions only.
4.3. Literature review
Apocrine carcinoma of the breast is seen in women between
6th and 7th decade. It is a rare cancer and its incidence is reported
between 0.3–4% of all female breast cancer [22] unlike a much
higher quoted incidence of 62% in one study [23]. This variation
is simply due to the fact that in the past there were no strict cri-
teria available to describe these lesions till Rosen [24] suggested
that apocrine cancers should be reserved for ‘neoplasms in which
all or nearly all the epithelium has apocrine cytological features
[24]. Japaze et al. [25] proposed a strict criteria to diagnose apoc-
rine lesions; this included 75% cells containing apocrine features
and the cells to be large in size containing eosinophilic cytoplasm
with sharply deﬁned borders. The cells have a nucleus to cytoplasm
ratio of 1:2 and contain large nucleoli.
Both our cases had typical features of apocrine tumours as the
criteria suggested with abundant eosinophilic cytoplasm in the
cells and nuclear pleomorphism.
One misconception regarding these tumours was the source
of its origin which was initially thought to arise from apocrine
sweat glands but this was  proved to be wrong and the true origin
of the apocrine cells was later conﬁrmed to arise in the terminal
duct-lobular unit [23]. These cancers do not express oestrogens
or progesterone receptors but there is over expression of human
epidermal growth factor and therefore these lesions are found
to be HER 2 positive except to occasional negativity to it as has
been reported by Tsutsumi [26]. The current recommendation now
is to test these cancers for androgen expressivity so the man-
agement could be more targeted in the form of anti-androgens.
This tumour is assessed immunohistochemically and in majority
of cases it expresses GCDFP-15 (76–100%) [22] which is a 15,000
Dalton monomer glycoprotein and is considered a speciﬁc tis-
sue marker of apocrine epithelium [27]. Interestingly, the levels
of GCDFP-15 decreases with advanced disease and also for node-
positive apocrine carcinoma [28].
Prognosis of these cancers is reported as same as the inﬁltrating
ductal cancers [29,30], but some studies have suggested a better 5
year survival than a non-apocrine carcinoma [22].Conﬂicts of interest
The authors declare that they have no competing interests.
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